Activated protein C receptor mod 
Welcome,         Profile    Billing    Logout  
 0 Companies  0 Products   0 Products   0 Diseases   0 Trials   0 News 


12345678910111213...1415»
  • ||||||||||  Review, Journal:  Deficiency of protein C or protein S as a possible cause of osteoporosis. (Pubmed Central) -  Mar 14, 2024   
    Moreover, when secondary causes of protein C and S deficiency are also considered, the proportion likely further increases. In this paper, we discuss the pathophysiological background of the potential relationship between protein C and S deficiency and the genesis of osteoporosis.
  • ||||||||||  Donesta (estetrol) / Mithra, Pantarhei
    Journal:  Low thrombin generation in postmenopausal women using estetrol. (Pubmed Central) -  Mar 13, 2024   
    P2
    As there was no VTE event during the study, further studies with larger numbers of patients will be needed to confirm that protein S-specific activity can be a surrogate maker of VTE risk. After 12?weeks of treatment, all treatment groups showed a mean thrombogram (
  • ||||||||||  Journal:  Activated protein C and free protein S in patients with mild to moderate bleeding disorders. (Pubmed Central) -  Mar 4, 2024   
    The downregulation of highly expressed AD biomarkers in 5xFAD could provide insight into the mechanisms by which APC administration benefits AD. Our data demonstrate increased antigen levels of APC in BDUC, which might contribute to the bleeding tendency in some patients and could be a future therapeutic target in BDUC.
  • ||||||||||  Journal:  Factor V variants in bleeding and thrombosis. (Pubmed Central) -  Feb 26, 2024   
    In particular, we discuss our current understanding of the 3 main pathological conditions related to FV, namely FV deficiency, activated protein C resistance, and the overexpression of FV-short, a minor splicing isoform of FV with tissue factor pathway inhibitor ?-dependent anticoagulant properties and an emerging role as a key regulator of the initiation of coagulation. Finally, we summarize relevant new data on this topic presented during the 2023 ISTH Congress.
  • ||||||||||  bleomycin / Generic mfg.
    Potential Role of Extracellular Vesicles in the Pathogenesis of Pleural Fibrosis (TDP12) -  Feb 20, 2024 - Abstract #ATS2024ATS_2068;    
    EVs were isolated from pleural effusions of patients with various diseases and from pleural lavage in two distinct mouse models: S. pneumoniae infection and carbon black-bleomycin administration (non-infectious)... Our study involving EV
  • ||||||||||  sirolimus / Generic mfg.
    Review, Journal:  Nutrition- and hormone-controlled developmental plasticity in Blattodea. (Pubmed Central) -  Nov 27, 2023   
    Insulin/insulin-like growth factor signaling (IIS), target of rapamycin complex 1 (TORC1), and adenosine monophosphate-activated protein complex are the three primary nutrition-responsive signals...We also highlight several perspectives that should be further emphasized in the studies of developmental plasticity in Blattodea. This review provides a general landscape in the field of nutrition- and hormone-controlled developmental plasticity in insects.
  • ||||||||||  Review, Journal:  Lactoferrin and Activated Protein C: Potential Role in Prevention of Cancer Progression and Recurrence. (Pubmed Central) -  Nov 9, 2023   
    Hence, in this review, the anticancer potential and mechanism of APC and LF along with their potential to mitigate inflammation and NETs-mediated cancer progression and recurrence has been discussed. Additionally, possible future strategies to develop effective and safe anticancer treatment using LF and APC have also been discussed in this review.
  • ||||||||||  Thrombosis in Young Women on Ocps Likely Is Caused By an Unmasking Effect of Estrogens on Underlying Thrombophilias (SDCC - Halls G-H) -  Nov 3, 2023 - Abstract #ASH2023ASH_5449;    
    All groups of females with a history of thrombosis had decreased mean %ETP reduction compared to healthy females not on OCPs (p=0.02), with the lowest values occurring in females with thrombosis following less than six months of OCP use. There was also a lower prevalence of abnormal CAT TM values amongst healthy controls not on OCPs as compared to thrombosis patients not on OCPs (19 vs 51%, p=0.005).Healthy females on OCPs showed an increased ETP (p=0.002) and a marked reduction in ELT (p<0.001) as compared to all other groups.
  • ||||||||||  SerpinPC (APC-specific serpin) / Centessa
    Serpin-PC in Persons with Severe Hemophilia (PwH): Updated Results from a Multicenter Multi-Part, First-in-Human Study (SDCC - Halls G-H) -  Nov 3, 2023 - Abstract #ASH2023ASH_3555;    
    Part 5 was a further extension in which subjects who completed Part 4 continued to receive 1.2 mg/kg of SerpinPC once every 2 weeks for 52 weeks. Results Annualized bleed rates, safety and tolerability for Part 5 will be available and a complete summary of all results to the end of Part 5 will be presented, including available pharmacokinetic and anti-drug antibody data.
  • ||||||||||  3K3A-APC / ZZ Biotech
    Intravenous 3K3A-Activated Protein C Inhibits Murine Ocular Inflammation and Suppresses Ocular Choroidal Neovascularization (SDCC - Halls G-H) -  Nov 3, 2023 - Abstract #ASH2023ASH_3537;    
    Drawing insights from the neuroprotective activities of 3K3A-APC in the brain and CNS and recognizing the retina, particularly the macula, as an extension of the brain, we propose 3K3A-APC as a potential neuroprotective treatment for AMD and other neurodegenerative retinal pathologies. Given the established safety of systemic 3K3A-APC administration in phase 2 clinical trials for ischemic stroke, our findings support further exploring 3K3A-APC as a novel therapeutic approach in ophthalmology.
  • ||||||||||  Survival Advantage Associated with Heterozygous Factor V Leiden Mutation in Sars-Cov-2-Infected K18-hACE2 Mice (SDCC - Halls G-H) -  Nov 3, 2023 - Abstract #ASH2023ASH_3496;    
    The protective effect of FV L heterozygosity may be attributable to enhanced thrombin formation which boosts inflammation and enhanced APC generation controlling proinflammatory and prothrombotic signaling, thus showing a delicate balance achieved by FV L heterozygosity that was lost for FV L homozygosity. As seen also in mouse models of bacterial sepsis, such favorable effects associated with FV L support the somewhat counterintuitive speculation that a partial increase in thrombin production in the early phase of the infection may support the resolution of COVID-19 complications.
  • ||||||||||  Review, Journal:  Activated protein C in epilepsy pathophysiology. (Pubmed Central) -  Oct 30, 2023   
    APC's activity acts on blood-brain barrier disruption, inflammation, and apoptosis and causes neurogenesis, all hallmarks that could potentially treat or prevent epilepsy. Here we review both Activated Protein C and epilepsy mechanism, function, and the possible association between them.
  • ||||||||||  warfarin / Generic mfg.
    RISK FOR ARTERIAL ISCHEMIC STROKE AND FACTOR V LEIDEN MUTATION: A CASE REPORT AND REVIEW () -  Oct 26, 2023 - Abstract #WSC2023WSC_1030;    
    Anticoagulant therapy, particularly including warfarin, may contribute to reducing risk for recurrent stroke in high-risk individuals with this mutation; however, careful monitoring is necessary due to increased bleeding risk. This article discusses the pathophysiology, disease characteristics, significance of the association between cerebral ischemic stroke and the mutation, risk factors for venous thromboembolism, and indications for anticoagulant therapy.
  • ||||||||||  pilocarpine / Generic mfg.
    Journal:  Activated protein C signaling mediates neuroinflammation in seizure induced by pilocarpine. (Pubmed Central) -  Oct 12, 2023   
    We propose that APC's protective effect could be associated with seizures through inflammation and apoptosis regulation. The results demonstrated that APC's pathway proteins are involved in neuroprotection mechanisms in seizure-induced models by acting on certain inflammatory factors, such as NF-?B and apoptosis proteins.
  • ||||||||||  paclitaxel / Generic mfg.
    Journal:  A spatially specified systems pharmacology therapy for axonal recovery after injury. (Pubmed Central) -  Oct 6, 2023   
    We applied, in gel foam at the site of nerve injury, Taxol to stabilize growing microtubules, and activated protein C to clear the debris field since computational models predicted that this drug combination regulating two subcellular processes at the growth cone produces synergistic growth...Morphology experiments show that the four-drug combination protects axons or promotes axonal regrowth to the optic chiasm and beyond. We conclude that spatially targeted drug treatment is therapeutically relevant and can restore limited functional recovery.
  • ||||||||||  HAPC1573 / Bayer, Shanghai RAAS
    Preclinical, Journal:  Safety and efficacy of anti-human activated protein C antibody SR604 for prophylaxis of congenital factor deficiencies. (Pubmed Central) -  Sep 22, 2023   
    We engineered a humanized chimeric antibody, SR604, based on a previously published murine antibody, HAPC1573, which selectively blocks the anticoagulant activity of human activated protein C (APC)...Pharmacokinetic study showed a high bioavailability (106%) of subcutaneous SR604 injection in cynomolgus monkeys. These results demonstrate that SR604 is expected to be a safe and effective therapeutic and/or prophylactic agent with a prolonged half-life for patients with congenital factor deficiencies including hemophilia A and B.